Associated Papers
Discovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold.
Zhong J et al.
Journal of Medicinal Chemistry, 2025
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.
Katayama Y et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Mechanisms of resistance to RET-directed therapies.
Clifton-Bligh RJ
Endocrine-related Cancer, 2025
Structure-Based Design of 2-Aminopyrazolpyrimidopyridone Derivatives as New Rearranged During Transfection (RET) Kinase Inhibitors.
Shen J et al.
Chemical Biology & Drug Design, 2025
Overview of management and therapeutic advances in medullary thyroid cancer.
Jara MA et al.
Endocrine Oncology (bristol, England), 2025
Fundamentals and recent advances in the evaluation and management of medullary thyroid carcinoma.
Gigliotti BJ et al.
Molecular and Cellular Endocrinology, 2024
Primary resistance to selpercatinib in a patient with advanced medullary thyroid cancer.
Pitoia F et al.
Endocrine, 2024
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Zhang Y et al.
Cell Communication and Signaling : Ccs, 2024
Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".
Spitaleri G et al.
Cancers, 2024
Developing Dynamic Structure-Based Pharmacophore and ML-Trained QSAR Models for the Discovery of Novel Resistance-Free RET Tyrosine Kinase Inhibitors Through Extensive MD Trajectories and NRI Analysis.
Sayyah E et al.
Chemmedchem, 2024
RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.
Hamidi S et al.
Annales D'endocrinologie, 2024
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Wang ZX et al.
Journal of Medicinal Chemistry, 2024
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.
Sahakian N et al.
Cancers, 2023
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms.
Porcelli T et al.
Jco Precision Oncology, 2023
Progress and challenges in RET-targeted cancer therapy.
Hu X et al.
Frontiers of Medicine, 2023
Medullary thyroid cancer - An update.
Fugazzola L
Best Practice & Research. Clinical Endocrinology & Metabolism, 2023
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
Servetto A et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2022
RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy.
Kucharczyk T et al.
Cancers, 2022
MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.
Saltiki K et al.
European Journal of Endocrinology, 2022
The Role of the Kinase Inhibitors in Thyroid Cancers.
Cuomo F et al.
Pharmaceutics, 2022
Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F et al.
Archives of Pharmacal Research, 2022
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.
Matrone A et al.
Frontiers in Endocrinology, 2022
RET kinase inhibitors for RET-altered thyroid cancers.
Vodopivec DM et al.
Therapeutic Advances in Medical Oncology, 2022
Precision oncology for RET-related tumors.
Verrienti A et al.
Frontiers in Oncology, 2022
Precision therapy for RET-altered cancers with RET inhibitors.
Thein KZ et al.
Trends in Cancer, 2021
Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.
Adashek JJ et al.
Molecular Cancer Therapeutics, 2021
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Saha D et al.
Journal of Medicinal Chemistry, 2021
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.
Moccia M et al.
Scientific Reports, 2021
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib.
Shen T et al.
Npj Precision Oncology, 2021
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
Subbiah V et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2021
Drug resistance profiles of mutations in the RET kinase domain.
Liu X et al.
British Journal of Pharmacology, 2018